CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.88−0.06 (-3.09%)
Close on Nov 18, 2026Market cap $409.65MP/E –Yield –
CytomX Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
CytomX Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$82.48M. For fiscal 2025 it was -$75.81M. The highest annual figure on record is $168.81M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$75.81M | – |
| FY2024 | Dec 31, 2024 | -$86.54M | – |
| FY2023 | Dec 31, 2023 | -$56.88M | – |
| FY2022 | Dec 31, 2022 | -$112.53M | – |
| FY2021 | Dec 31, 2021 | -$120.64M | -4189.5% |
| FY2020 | Dec 31, 2020 | $2.95M | – |
| FY2019 | Dec 31, 2019 | -$143.98M | – |
| FY2018 | Dec 31, 2018 | -$79.31M | -147.0% |
| FY2017 | Dec 31, 2017 | $168.81M | – |
| FY2016 | Dec 31, 2016 | -$4.21M | – |
| FY2015 | Dec 31, 2015 | -$29.01M | -196.3% |
| FY2014 | Dec 31, 2014 | $30.14M | – |
| FY2013 | Dec 31, 2013 | -$8.74M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.07M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.55M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.44M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.42M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.78M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$19.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.75M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -$26.16M | -381.3% |
| Q4 FY2023 | Dec 31, 2023 | -$22.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.70M | – |
| Q1 FY2023 | Mar 31, 2023 | $9.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.58M | – |
| Q3 FY2022 | Sep 30, 2022 | -$34.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$34.65M | – |
| Q1 FY2022 | Mar 31, 2022 | -$42.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$31.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$29.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$28.31M | -129.2% |
| Q1 FY2021 | Mar 31, 2021 | -$30.92M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.87M | – |
| Q3 FY2020 | Sep 30, 2020 | -$25.46M | – |
| Q2 FY2020 | Jun 30, 2020 | $97.06M | – |
| Q1 FY2020 | Mar 31, 2020 | -$50.79M | – |
| Q4 FY2019 | Dec 31, 2019 | -$30.18M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.95M | – |
| Q2 FY2019 | Jun 30, 2019 | -$48.98M | – |
| Q1 FY2019 | Mar 31, 2019 | -$40.86M | – |
| Q4 FY2018 | Dec 31, 2018 | -$29.86M | -237.2% |
| Q3 FY2018 | Sep 30, 2018 | -$6.60M | – |
| Q2 FY2018 | Jun 30, 2018 | -$27.48M | -115.9% |
| Q1 FY2018 | Mar 31, 2018 | -$15.36M | – |
| Q4 FY2017 | Dec 31, 2017 | $21.77M | +1531.8% |
| Q3 FY2017 | Sep 30, 2017 | -$5.80M | – |
| Q2 FY2017 | Jun 30, 2017 | $172.87M | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.03M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.33M | – |
| Q3 FY2016 | Sep 30, 2016 | -$15.05M | – |
See a number that looks wrong?